/

OLMA

Olema Pharmaceuticals, Inc.Open

7.06−0.31 −4.14%USD

NasdaqGS · as of Oct 13, 15:49 ET · 15m delay

Open

7.30

Prev close

7.36

Day range

7.057.36

52-week range

6.6536.26

Volume

947.85K0.90×

Mkt cap

617.30M

P/E ttm

—

Fwd P/E

-2.68

EPS ttm

-2.12

Div yield

0.00%

Earnings

—

From 52w high

−80.54%

Price Chart

Yahoo Finance · delayed

OLMAOct 13, 2026O 7.30H 7.36L 7.05C 7.05−0.31 (−4.14%)Vol 947.85K

SMA 509.92
SMA 20015.29

1Y change −33.25% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

OLMA Olema Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −10.92%
1 month: −30.97%
3 months: −40.46%
6 months: −56.72%
Year to date: −71.78%
1 year: −34.37%

Valuation & ownership

Market cap: 617.30M
Enterprise value: 186.57M
P/E (ttm): —
Forward P/E: -2.68
PEG ratio: —
Price / book: 1.43
Price / sales (ttm): —
EV / EBITDA: -0.84
EPS (ttm): -2.12
EPS (forward): -2.64
Beta (5y monthly): 2.01
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 87.50M
Float: 59.24M
Short % of float: 20.40%
Short ratio (days): 11.88
Held by insiders: 1.76%
Held by institutions: 119.63%
Avg volume (3m): 1.05M
50-day average: 10.01
200-day average: 15.39
52-week change: −34.37%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 18.6
vs 50-day SMA: −28.90%
vs 200-day SMA: −53.86%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.89%
Realised vol (20d, ann.): 43.9%
From 52-week high: −80.54%
From 52-week low: +6.09%

ANR

Analyst Consensus

10 analysts

Consensus

—

Mean target

36.50

+417.36% implied

Low 16.00Median 38.00High 59.00

Recommendation trend

Now11 / 1 / 0
1m ago11 / 1 /

DES

About Olema Pharmaceuticals, Inc.

Yahoo Finance profile

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 150
Headquarters: San Francisco, CA, United States
Website: olema.com
Officers: Dr. Sean P. Bohen M.D., Ph.D. President, CEO & Director

SEAS

Seasonality · OLMA

2020–2026 · monthly returns

Strongest month Nov +23.44%Weakest month Feb −16.34%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	2.9	-5.9	-38.4	-3.4	-8.5	-5.2	-8.5	-8.9	-17.2	-18.3			−71.8%
2025	4.8	-28.5	-14.0	37.2	2.3	-19.3	20.7	6.2	79.3	-8.4	215.7	-11.7	+328.8%
2024	-7.1	-4.9	-8.7	-10.2	-4.8	11.8	49.4	-27.0	1.2	-3.4	-12.2	-42.4	−58.4%
2023	97.1	-15.1	-15.4	38.0	7.9	74.7	-4.2	17.3	21.7	7.6	5.0	0.6	+472.7%
2022	-31.3	-27.2	-9.0	-40.1	12.2	42.3	23.3	-21.3	-30.1	36.2	-23.7	-14.6	−73.8%
2021	-11.7	-6.0	-16.9	-15.5	-0.3	0.1	-16.1	27.4	-7.9	-2.0	-67.6	7.0	−80.5%
2020												-5.7	−5.7%

INSD

Insider Activity · OLMA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 23, 2026	Harmon CyrusDirector	Sale at price 11.58 - 11.71 per share.	25K	$291.16K
Mar 3, 2026	Mitchell ShawnteOfficer	Conversion of Exercise of derivative security at price 4.37 per share.	40K	$174.80K
Mar 3, 2026	Mitchell ShawnteOfficer	Sale at price 23.01 - 24.69 per share.	40K	$951.50K
Feb 1, 2026	Austin Sasha LuOfficer	Stock Award(Grant) at price 0.00 per share.	11.7K	—
Jan 19, 2026	Harmon CyrusDirector	Sale at price 26.88 per share.	10K	$268.80K
Jan 14, 2026	Kovacs Shane William CharlesChief Operating Officer	Sale at price 28.01 - 28.73 per share.	103.8K	$2.98M
Jan 13, 2026	Myles David COfficer	Conversion of Exercise of derivative security at price 4.87 per share.	100K	$487.00K
Jan 13, 2026	Harmon CyrusDirector	Sale at price 29.12 per share.	3.5K	$101.60K
Jan 13, 2026	Myles David COfficer	Sale at price 27.60 - 28.99 per share.	110K	$3.11M
Dec 25, 2025	Bohen SeanChief Executive Officer	Stock Gift at price 0.00 per share.	8.5K	—
Dec 22, 2025	Zojwalla Naseem M.D.Officer	Conversion of Exercise of derivative security at price 7.02 - 15.25 per share.	140K	$1.66M
Dec 22, 2025	Zojwalla Naseem M.D.Officer	Sale at price 27.66 - 28.93 per share.	269.5K	$7.53M
Dec 21, 2025	Harmon CyrusDirector	Sale at price 28.53 per share.	2.9K	$82.19K
Dec 18, 2025	Myles David COfficer	Stock Gift at price 0.00 per share.	9K	—
Dec 18, 2025	Clark Ian ThorntonDirector	Conversion of Exercise of derivative security at price 3.61 - 7.84 per share.	264.8K	$1.22M
Dec 18, 2025	Clark Ian ThorntonDirector	Sale at price 28.83 - 30.48 per share.	264.8K	$7.87M
Dec 18, 2025	Myles David COfficer	Sale at price 28.08 - 31.39 per share.	51K	$1.55M
Dec 7, 2025	Kovacs Shane William CharlesOfficer	Stock Gift at price 0.00 per share.	75K	—
Nov 25, 2025	Kovacs Shane William CharlesChief Operating Officer	Stock Gift at price 0.00 per share.	225K	—
Nov 24, 2025	Rappaport Andrew SDirector	Stock Gift at price 0.00 per share.	35.9K	—

13F

Investors Holding OLMA

latest 13F filings of 29 followed managers

Investors holding OLMA
Investor	Value	Of portfolio	Shares	Change	Quarter
Duquesne Family Office · Stanley Druckenmiller	$12.3M	0.24%	986.83K	—	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

OLMA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

OLMA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Olema Pharmaceuticals, Inc.

Seasonality · OLMA

Insider Activity · OLMA

Congress Trades · OLMA

Investors Holding OLMA

Investors Holding OLMA

Congress Trades · OLMA

Insider Activity · OLMA

Seasonality · OLMA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Olema Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News